Oncology EGFR-mutant lung cancer: Cracking the drug resistance code Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade.
News Rhapsido is first drug cleared for chronic hives disorder SD Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
